IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process

Points To ‘Limited Value’ Of Efficacy Data; Urges Renewed Education Efforts

 
• By David Wallace
  
Efficacy_Sign
Comparative efficacy clinical data is largely surplus to requirements, the IGBA says • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products